Cue Health Inc., a healthcare technology company, today reported financial results for the first quarter 2023.

Siemens Healthineers AG today announces its results for the second quarter, ending March 31, of fiscal year 2023.

Sansure Biotech announced that the company will invest CNY 90.93 million, accounting for 53.2% of the shares, and jointly establish Hunan Sansure Ansai Biotechnology.

Invitae, a leading medical genetics company, announced financial and operating results for the first quarter ended March 31, 2023.

DiaSorin said that its first quarter 2023 revenues fell 19 percent year over year on a sharp decline in COVID-19 testing, partially offset by growth in its non-COVID-19-related diagnostics revenues.

Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia.

BioMérieux announced on Tuesday that its BioFire SpotFire Respiratory Panel Mini has obtained CLIA wavier from the US Food and Drug Administration.

The US Food and Drug Administration (FDA) has granted approval for Foundation Medicine’s FoundationOne Liquid CDx as a companion diagnostic for Takeda’s Exkivity (mobocertinib).

Veracyte, Inc. today announced financial results for the first quarter ended March 31, 2023.

On April 25-26, Yin Ye, CEO of BGI Genomics, and his delegation visited Serbia and signed a memorandum of understanding with the Serbian Ministry of Health on cooperation in public health and precision testing.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023.

BD, a leading global medical technology company, today announced results for its second quarter of fiscal 2023, which ended March 31, 2023.

The World Health Organization on Friday announced that COVID-19 is no longer a global emergency, marking a symbolic end to the pandemic, which has taken 7 million lives around the world. The move is deemed a natural one given the current stable situation.

A spokesperson from Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) recently responded to investors' questions about chemiluminescence at the 2022 Annual Investor Exchange.

QIAGEN announced results for the first quarter of 2023.